Supernus Pharmaceuticals, Inc.
SUPN
Rang in aandelen
#5603
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Aandeelprijs
$41.34
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$2.41B
Verandering (1 dag)
3.75%
Verandering (1 jaar)
-18.52%
Land
US
Handel Supernus Pharmaceuticals, Inc. (SUPN)
Categorie
Healthcare
Aandelsplitsingen voor Supernus Pharmaceuticals, Inc. (SUPN)
Het aandeel Supernus Pharmaceuticals, Inc. (symbool: SUPN) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 21, 2026.
Eén aandeel SUPN dat vóór Oct 21, 2026 werd gekocht, staat nu gelijk aan 0 aandelen SUPN.
De meest recente splitsing vond plaats op Oct 21, 2026.
Eén aandeel SUPN dat vóór Oct 21, 2026 werd gekocht, staat nu gelijk aan 0 aandelen SUPN.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | |||
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 0 | - |
DE
|
|
| 0 | - |
DE
|
|
| 0 | - |
JP
|
|
| 0 | - |
CH
|
|
| 5 | x119 |
IN
|
